case / 26 Mar 2024

Setterwalls advises Alligator Bioscience in connection with rights issue of approximately SEK 150 million

Responsive image

Setterwalls advises Alligator Bioscience AB (“Alligator”), listed on Nasdaq Stockholm, in connection with a rights issue of units of approximately SEK 150 million with an over-allotment issue of up to an additional approximately SEK 100 million.

Alligator is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs. Alligator’s shares are listed on Nasdaq Stockholm, and the company is headquartered in Lund, Sweden.

Do you want to get in touch with us?

Please fill out the form and we will contact you as soon as possible.

  • This field is for validation purposes and should be left unchanged.